Teladoc Health (NYSE:TDOC) Stock

Teladoc Health

Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.

ASTSpaceMobile.Screenshotvideo

Equities

Mid Cap

News

Movers

Tech

Trading Ideas

ASTS

IREN

MGNI

OKLO

TDOC

VNET

Top mid-cap stock performers last week: Kingsoft Cloud up 34.77%, Oklo Inc. up 33.36%, AST SpaceMobile up 30.98%, VNET Group up 29.12%, Teladoc Health up 27.46%, GDS Holdings up 25.68%, Magnite up 23.08%, SolarWinds up 23.05%, Lions Gate Entertainment up 22.68%, IREN Limited up 22.02%.

AST SpaceMobile, Teladoc Health And IREN Are Among Top 10 Mid Cap Gainers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio?

Teladoc_Member_and_Child_on_Video_Visit-3

Contracts

AMZN

KraneShares Trust KraneShares Man Buyout Beta Index ETF

BUYO

Teladoc Health (NYSE: TDOC) partners with Amazon (NASDAQ: AMZN) to expand access to its chronic condition management programs. 

Teladoc Stock Gains As Amazon Partnership Fuels Push for Consumer-Centric Healthcare

Hims & Hers Health, Inc. Class A Common Stock

HIMS


The Trump administration has nominated Dr. Marty Makary for the role of the United States Federal Drug Administration (FDA) commissioner. Dr. Makary is the Chief of Islet Transplant Surgery at Johns Hopkins University

2 Telehealth Stocks That Could Gain from Trump&#39;s New FDA Pick

Teladoc Health Inc

<a href="https://www.blueorcacapital.com/blue-orca-is-short-teladoc-health-inc/" title="https://www.blueorcacapital.com/blue-orca-is-short-teladoc-health-inc/">https://www.blueorcacapital.com/blue-orca-is-short-teladoc-health-inc/</a>

Short Sellers

Watching Teladoc Health; 'Blue Orca Capital Is Short Teledoc Health' Issues Report On The Company

Goldman Sachs analyst David Roman maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Buy and raises the price target from $14 to $16.

Price Target

Analyst Ratings

Goldman Sachs Maintains Buy on Teladoc Health, Raises Price Target to $16

6 analysts have shared their evaluations of Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $12.67, a high estimate of $14.00, and a low estimate of $11.50. This upward trend is evident, with the current average reflecting a 9.22% increase from the previous average price target of $11.60.
<img src="https://www.benzinga.com/files/images/story/2025/1739368852_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Teladoc Health among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$13.50</td>
<td>$11.50</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$11.50</td>
<td>$10.50</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$14.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Teladoc Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Teladoc Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Teladoc Health's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Teladoc Health analyst ratings.</a>
<h2>Discovering Teladoc Health: A Closer Look</h2>
Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.
<h3>Teladoc Health: A Financial Overview</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Teladoc Health's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -2.99%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Teladoc Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -5.2%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Teladoc Health's ROE stands out, surpassing industry averages. With an impressive ROE of -2.21%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Teladoc Health's ROA excels beyond industry benchmarks, reaching -0.94%. This signifies efficient management of assets and strong financial health.
Debt Management: Teladoc Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.05.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Teladoc Health: Insights From 6 Financial Analysts

B of A Securities analyst Allen Lutz maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Neutral and raises the price target from $11.5 to $13.5.

B of A Securities Maintains Neutral on Teladoc Health, Raises Price Target to $13.5

Deep-pocketed investors have adopted a bullish approach towards Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TDOC usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for Teladoc Health. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 33% bearish. Among these notable options, 2 are puts, totaling $100,220, and 10 are calls, amounting to $394,909.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $7.5 to $17.5 for Teladoc Health over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Teladoc Health options trades today is 1654.0 with a total volume of 13,969.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Teladoc Health's big money trades within a strike price range of $7.5 to $17.5 over the last 30 days.
<h3>Teladoc Health Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739220323_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TDOC</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$4.55</td>
<td>$4.45</td>
<td>$4.5</td>
<td>$10.00</td>
<td>$90.0K</td>
<td>3.6K</td>
<td>237</td>
</tr>
<tr>
<td>TDOC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$1.85</td>
<td>$1.6</td>
<td>$1.85</td>
<td>$12.50</td>
<td>$74.0K</td>
<td>175</td>
<td>407</td>
</tr>
<tr>
<td>TDOC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$0.9</td>
<td>$0.82</td>
<td>$0.88</td>
<td>$14.00</td>
<td>$57.0K</td>
<td>3.7K</td>
<td>2.4K</td>
</tr>
<tr>
<td>TDOC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$0.92</td>
<td>$0.82</td>
<td>$0.82</td>
<td>$17.50</td>
<td>$41.0K</td>
<td>2.2K</td>
<td>912</td>
</tr>
<tr>
<td>TDOC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$7.15</td>
<td>$6.8</td>
<td>$6.89</td>
<td>$10.00</td>
<td>$34.4K</td>
<td>538</td>
<td>93</td>
</tr>
</tbody>
</table>

<h3>About Teladoc Health</h3>
Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.
Following our analysis of the options activities associated with Teladoc Health, we pivot to a closer look at the company's own performance.
<h3>Current Position of Teladoc Health</h3>
<ul>
<li>With a trading volume of 14,344,358, the price of TDOC is up by 7.14%, reaching $13.88.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 16 days from now.</li>
</ul>
<h3>Expert Opinions on Teladoc Health</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $11.833333333333334.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from B of A Securities has decided to maintain their Neutral rating on Teladoc Health, which currently sits at a price target of $11. 
&#x2A; An analyst from RBC Capital persists with their Outperform rating on Teladoc Health, maintaining a target price of $12. 
&#x2A; An analyst from Oppenheimer persists with their Outperform rating on Teladoc Health, maintaining a target price of $12. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Teladoc Health, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Unpacking the Latest Options Trading Trends in Teladoc Health

These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Kingsoft Cloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) stock upped 34.77%.</li>
<li>Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) stock jumped 33.36%. Board member Chris Wright was confirmed as the U.S. Secretary of Energy on February 3, 2025. As a result, he has <a href="https://www.benzinga.com//node/43525625" target="_blank" rel="noreferrer noopener">stepped down from Oklo's Board</a>.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) shares escalated 30.98% after Cantor Fitzgerald analyst Colin Canfield initiated coverage with an Overweight rating <a href="https://www.benzinga.com/quote/ASTS/analyst-ratings" target="_blank" rel="noreferrer noopener">and price forecast of&nbsp;$30</a>.</li>
<li>VNET Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>) shares surged 29.12%.</li>
<li>Teladoc Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) shares rose 27.46% after the company announced it would acquire Catapult Health in an all-<a href="https://www.benzinga.com//node/43490439" target="_blank" rel="noreferrer noopener">cash $65 million transaction</a>.</li>
<li>GDS Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) shares were up 25.68%.&nbsp;China recently raised tariffs on certain U.S. imports, and reports suggested that the U.S. is exploring adding Shein and Temu to the ‘forced labor' list.</li>
<li>Magnite, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) stock gained 23.08% last week following a report indicating <a href="https://www.businessinsider.com/elon-musk-x-signs-programmatic-ad-partnership-magnite-2025-2" target="_blank" rel="noreferrer noopener">it signed a partnership</a> with Elon Musk's X, formerly Twitter.</li>
<li>SolarWinds Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWI#NYSE">SWI</a>) stock grew 23.05% after the company announced that Turn/River Capital would acquire it <a href="https://www.benzinga.com//node/43559292" target="_blank" rel="noreferrer noopener">for &nbsp;$4.4 billion</a>.</li>
<li>Lions Gate Entertainment Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LGF#NYSE">LGF</a>) stock upped 22.68% last week after the company reported better-than-expected Q3 earnings.</li>
<li>IREN Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) shares rose 22.02% last week <a href="https://www.benzinga.com//node/43524343" target="_blank" rel="noreferrer noopener">after reporting it mined</a> 525 Bitcoins (CRYPTO: BTC/USD) in January.</li>
</ol>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/02/43580845/palantir-super-micro-computer-and-spotify-are-among-top-10-large-cap-gainers-last-week-feb-3-feb-7-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Palantir, Super Micro Computer And Spotify Are Among Top 10 Large Cap Gainers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/large-cap/25/02/43580887/estee-lauder-moderna-and-paypal-are-among-top-10-large-cap-losers-last-week-feb-3-feb-7-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Estee Lauder, Moderna And PayPal Are Among Top 10 Large Cap Losers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via ASTS

WIIM

Teladoc shares are trading higher on continued strength amid bullish comments Citron Research.

Investors with a lot of money to spend have taken a bullish stance on Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TDOC, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Teladoc Health.
This isn't normal.
The overall sentiment of these big-money traders is split between 66% bullish and 33%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $80,790, and 7 are calls, for a total amount of $305,754.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $7.5 to $35.0 for Teladoc Health over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Teladoc Health's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Teladoc Health's whale activity within a strike price range from $7.5 to $35.0 in the last 30 days. 
<h3>Teladoc Health 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738942237_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TDOC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.83</td>
<td>$2.8</td>
<td>$2.83</td>
<td>$15.00</td>
<td>$86.5K</td>
<td>4.0K</td>
<td>1.4K</td>
</tr>
<tr>
<td>TDOC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$3.35</td>
<td>$3.1</td>
<td>$3.35</td>
<td>$12.50</td>
<td>$46.7K</td>
<td>486</td>
<td>140</td>
</tr>
<tr>
<td>TDOC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$0.8</td>
<td>$0.8</td>
<td>$0.8</td>
<td>$15.00</td>
<td>$45.5K</td>
<td>3.2K</td>
<td>1.4K</td>
</tr>
<tr>
<td>TDOC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$5.95</td>
<td>$5.85</td>
<td>$5.85</td>
<td>$17.50</td>
<td>$43.2K</td>
<td>0</td>
<td>75</td>
</tr>
<tr>
<td>TDOC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.52</td>
<td>$1.32</td>
<td>$1.5</td>
<td>$12.50</td>
<td>$37.5K</td>
<td>3.7K</td>
<td>465</td>
</tr>
</tbody>
</table>

<h3>About Teladoc Health</h3>
Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.
Having examined the options trading patterns of Teladoc Health, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Teladoc Health</h3>
<ul>
<li>With a trading volume of 4,468,528, the price of TDOC is up by 3.43%, reaching $12.38.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 19 days from now.</li>
</ul>
<h3>What The Experts Say On Teladoc Health</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $11.833333333333334.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for Teladoc Health, targeting a price of $12. 
&#x2A; An analyst from B of A Securities persists with their Neutral rating on Teladoc Health, maintaining a target price of $11. 
&#x2A; An analyst from Oppenheimer persists with their Outperform rating on Teladoc Health, maintaining a target price of $12. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Teladoc Health, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Check Out What Whales Are Doing With TDOC

<a href="https://x.com/CitronResearch/status/1887875209966805075" title="https://x.com/CitronResearch/status/1887875209966805075">https://x.com/CitronResearch/status/1887875209966805075</a>

DOCS

Citron Research Posts On X "$TDOC got solid feedback on yesterday's post. Look at $DOCS today—digital tools fueling the telemedicine boom. Read their report:..."

Teladoc Health shares are trading higher amid a post from CitronResearch on X stating the company is "quietly turning into a cash-generating machine". Also, B of A Securities raised its price target on the stock from $10.5 to $11.5.

CitronResearch Tweeted $TDOC – The Under-the-Radar AI Play Teladoc just acquired Catapult Health, doubling down on preventive care + virtual health. The market still treats it like a pandemic relic, but it's quietly turning into a cash-generating machine. While AI hype stocks trade at wild multiples

B of A Securities analyst Allen Lutz maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Neutral and raises the price target from $10.5 to $11.5.

B of A Securities Maintains Neutral on Teladoc Health, Raises Price Target to $11.5

Teladoc Health shares are trading higher after the company announced it will acquire Catapult Health in an all-cash $65 million transaction.

Catapult Health's trailing twelve-month revenue was approximately $30 million as of the third quarter of 2024. The transaction is expected to close in the first quarter of 2025, subject to customary closing conditions.
Following the closing of the transaction, Catapult Health will operate within the Integrated Care segment of Teladoc Health.
 &nbsp;

Teladoc Health To Acquire Catapult Health In An All-cash Transaction For $65M, With Up To $5M In Additional Contingent Earnout Consideration

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Teladoc Health, revealing an average target of $11.86, a high estimate of $14.00, and a low estimate of $8.00. This upward trend is evident, with the current average reflecting a 9.51% increase from the previous average price target of $10.83.
<img src="https://www.benzinga.com/files/images/story/2025/1737752448_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of Teladoc Health by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$14.00</td>
<td>-</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$12.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Steve Valiquette</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Teladoc Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Teladoc Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Teladoc Health's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Teladoc Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Teladoc Health</h2>
Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.
<h3>Teladoc Health's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Teladoc Health's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -2.99%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Teladoc Health's net margin excels beyond industry benchmarks, reaching -5.2%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Teladoc Health's ROE excels beyond industry benchmarks, reaching -2.21%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Teladoc Health's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.94% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Teladoc Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.05.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Teladoc Health Through The Eyes Of 7 Analysts

RBC Capital analyst Sean Dodge maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Outperform and raises the price target from $11 to $12.

RBC Capital Maintains Outperform on Teladoc Health, Raises Price Target to $12

Oppenheimer analyst Michael Wiederhorn maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Outperform and lowers the price target from $14 to $12.

Oppenheimer Maintains Outperform on Teladoc Health, Lowers Price Target to $12

Teladoc Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) short percent of float has risen 3.62% since its last report. The company recently reported that it has 23.53 million shares sold short, which is 17.76% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.71 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Teladoc Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737060311_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teladoc Health has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Teladoc Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Teladoc Health's peer group average for short interest as a percentage of float is 5.32%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Ideas

Looking Into Teladoc Health's Recent Short Interest

Teladoc Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) shares are trading higher premarket on Tuesday. On Monday, the company disclosed a partnership with Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) to broaden access to its chronic <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42964279/teladoc-health-joins-amazons-health-benefits-connector-for-cardiometabolic-programs" rel="noreferrer noopener">condition management programs</a>.
Teladoc Health's chronic condition programs serve over 1 million active enrollees, utilizing connected devices, data-driven personalization, and expert coaching to promote lasting behavior changes and improve cardiometabolic health outcomes.
The company supports over 1 million enrollees in its chronic condition programs, using connected devices, personalized data, and expert coaching to improve cardiometabolic health.
Eligible Amazon customers can now discover and enroll in Teladoc's programs for diabetes, hypertension, pre-diabetes, and weight management through Amazon's Health Benefits Connector, previously known as Health Condition Programs.
Notably, over half of U.S. adults have a chronic condition, yet many face barriers to accessing digital health programs, the company said in the press release. Nearly 25% are unaware of their full health plan benefits.
Amazon's Health Benefits Connector addresses this by highlighting eligible benefits during product searches. Teladoc Health's participation reflects a joint effort to prioritize consumer-centric healthcare solutions.
Investors can gain exposure to the stock via KraneShares Trust KraneShares Man Buyout Beta Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUYO#NYSE">BUYO</a>).
<h2 class="wp-block-heading">Teladoc Health Stock Prediction for 2025</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Teladoc Health, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Teladoc Health, the 200-day moving average sits at $10.07, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, which is above the current price of $9.7. For more on charts and trend lines, <a href="https://pro.benzinga.com/">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: TDOC shares are up 7.94% at $10.47 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/content/42362891/2-telehealth-stocks-that-could-gain-from-trumps-new-fda-pick" target="_blank" rel="noreferrer noopener">2 Telehealth Stocks That Could Gain from Trump's New FDA Pick</a></li>
</ul>
Photo: courtesy of Teladoc.

General

Teladoc Health shares are trading higher after the company joined Amazon's Health Benefits Connector for its cardiometabolic programs.

Press Releases

Teladoc Health to Participate in Upcoming Investor Conference

Health Care

Teladoc Health Joins Amazon's Health Benefits Connector for Cardiometabolic Programs

How HealthCare Industry is Leveraging Artificial Intelligence to Revolutionize Diagnostics and Early Disease Detection

Small Cap

Opinion

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028

Potential Revolution in Healthcare Brewing, Powered by AI Innovation

Teladoc Health to Announce Fourth Quarter 2024 Financial Results

Teladoc Health to Acquire Catapult Health, Advancing Integrated Care Strategy

Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08

Legal

TDOC INVESTIGATION: Teladoc Health, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation Teladoc Health Inc. (NYSE: TDOC) and Urges Investors with Substantial Losses to Contact the Firm

Comments

Teladoc Health

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga